Article Versions Notes

Delgado T, Veselá D, Dostálová H, Kryštof V, Vojáčková V, Jorda R, Castro A, Bertrand J, Rivera G, Faúndez M, et al. New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs. Pharmaceutics. 2024; 16(5):649. https://doi.org/10.3390/pharmaceutics16050649

Delgado, Thalia, Denisa Veselá, Hana Dostálová, Vladimír Kryštof, Veronika Vojáčková, Radek Jorda, Alejandro Castro, Jeanluc Bertrand, Gildardo Rivera, Mario Faúndez, and et al. 2024. "New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs" Pharmaceutics 16, no. 5: 649. https://doi.org/10.3390/pharmaceutics16050649

Delgado, T., Veselá, D., Dostálová, H., Kryštof, V., Vojáčková, V., Jorda, R., Castro, A., Bertrand, J., Rivera, G., Faúndez, M., Strnad, M., Espinosa-Bustos, C., & Salas, C. O. (2024). New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs. Pharmaceutics, 16(5), 649. https://doi.org/10.3390/pharmaceutics16050649